Ypsomed Holding AG - Company Profile

Powered by

All the data and insights you need on Ypsomed Holding AG in one report.

$395 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Ypsomed Holding AG Strategy Report

  • Understand Ypsomed Holding AG position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Ypsomed Holding AG: Overview

Select Item

Related keylists

Ypsomed Holding AG (Ypsomed) is a medical device company that designs, develops and manufactures injection and infusion systems for self-medication and offers related services. It offers autoinjectors, dual chamber pens, and pen injectors. The company also offers services ranging from design and development projects, flexible prototyping, human factors engineering, monitoring services, therapy management and IP landscape management to manufacturing and assembly infrastructure and registration support. Ypsomed offers solutions to physicians, pharmaceutical and biotechnology companies. The company's products find application in the treatment of diabetes, infertility, growth disorders and various other clinical indications. The company has its operations in Australia, Austria, Czechia, Denmark, Finland, France, Germany, India, Italy, the Netherlands, Norway, Sweden, Switzerland, United Kingdom, Belgium, China, Canada, Poland, Spain and the US. Ypsomed is headquartered in Burgdorf, Switzerland.

 Gain a 360-degree view of Ypsomed Holding AG and make more informed decisions for your business Gain a 360-degree view of Ypsomed Holding AG and make more informed decisions for your business Find out more
Headquarters Switzerland
Address Brunnmattstrasse 6, Burgdorf, 3401
Website www.ypsomed.com
Telephone 41 34 4244111
No of Employees 2,200
Industry Medical Equipment
Ticker Symbol & Exchange YPSN (SWF)
Revenue (2022) $521.1M 7% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 121.9% (2022 vs 2021)
Market Cap* $5.7B
Net Profit Margin (2022) XYZ 107.4% (2022 vs 2021)
* As of and is in US$
View Ypsomed Holding AG financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Ypsomed Holding AG premium industry data and analytics

8

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

3

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Ypsomed Holding AG’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Services Brands
Delivery Systems: Contract manufacturing Penfine
Autoinjectors Design and Development Services Universal Click
Pen Injectors Prototyping Humatro-Pen
XYZ XYZ XYZ
XYZ XYZ XYZ
XYZ XYZ XYZ
Understand Ypsomed Holding AG portfolio and identify potential areas for collaboration Understand Ypsomed Holding AG portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In October, the company signed a supply agreement with Viridian Therapeutics to customize and supply YpsoMate 2.25 patient-administered delivery devices to support Viridian’s development of investigational subcutaneous therapy candidates for the treatment of thyroid eye disease.
2023 New Products/Services In October, the company announced new Human Factors services.
2023 Contracts/Agreements In September, the company entered into a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Ypsomed Holding AG Johnson & Johnson F. Hoffmann-La Roche Ltd Sanofi Abbott Laboratories
Headquarters Switzerland United States of America Switzerland France United States of America
City Burgdorf New Brunswick Basel Paris Abbott Park
State/Province - New Jersey - Ile-de-France Illinois
No. of Employees 2,200 131,900 103,605 87,994 114,000
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Gilbert Achermann Chairman Executive Board 2022 59
Simon Michel Chief Executive Officer; Director Executive Board 2014 46
Samuel Kunzli Chief Financial Officer Senior Management 2024 60
Frank Mengis Chief Operating Officer Senior Management 2015 59
Nicolas Meyer Chief Legal Officer Senior Management 2023 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Ypsomed Holding AG key executives to enhance your sales strategy Gain insight into Ypsomed Holding AG key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Why are you leaving?